Get the Stockscreener App
0.6648
2.04%
-0.0152
Werewolf Therapeutics Inc stock is traded at $0.6648, with a volume of 582.59K.
It is down -2.04% in the last 24 hours and down -21.54% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
See More
Previous Close:
$0.68
Open:
$0.6824
24h Volume:
582.59K
Relative Volume:
1.44
Market Cap:
$32.30M
Revenue:
$1.14M
Net Income/Loss:
$-60.82M
P/E Ratio:
-0.4984
EPS:
-1.3338
Net Cash Flow:
$-60.29M
1W Performance:
-3.46%
1M Performance:
-21.54%
6M Performance:
-41.05%
1Y Performance:
-16.72%
1-Day Range:
$0.6518
$0.7159
1-Week Range:
$0.61
$0.78
52-Week Range:
$0.5301
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.6647 | 33.05M | 1.14M | -60.82M | -60.29M | -1.3338 |
VRTX
Vertex Pharmaceuticals Inc
|
435.33 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
704.10 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.88 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.24 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
310.34 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
HOWL SEC FilingsWerewolf Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Werewolf sells JZP898 rights to Jazz, repays K2 debt amid review - Stock Titan
Werewolf Therapeutics director Luke Evnin sells $64,216 in shares - Investing.com UK
Werewolf Therapeutics director Luke Evnin sells $64,216 in shares By Investing.com - Investing.com Nigeria
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates - Investing News Network
Funds tied to Werewolf Therapeutics (HOWL) director sell 100,581 shares - Stock Titan
Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Strategic review, Jazz asset sale and Q1 loss at Werewolf Therapeutics (NASDAQ: HOWL) - Stock Titan
[10-Q] Werewolf Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Werewolf Therapeutics (ticker: HOWL) holders detail stake and sales in 13D/A - Stock Titan
How Werewolf Therapeutics (HOWL) earnings power compares to its price (Mini Selloff) 2026-05-05Certified Trade Ideas - newser.com
Werewolf Therapeutics director Luke Evnin sells $198,309 in shares - Investing.com
Werewolf Therapeutics director Luke Evnin sells $198,309 in shares By Investing.com - Investing.com South Africa
Werewolf Therapeutics (NASDAQ: HOWL) entities sell 274K shares - Stock Titan
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
Werewolf Therapeutics (HOWL) price target increased by 12.00% to 7.14 - MSN
Werewolf Therapeutics director Luke Evnin sells $154,525 in stock By Investing.com - Investing.com Australia
Werewolf Therapeutics director Luke Evnin sells $154,525 in stock - Investing.com
Werewolf Therapeutics (HOWL) stake trimmed by MPM entities in planned sales - Stock Titan
MSN Money - MSN
Werewolf Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
HOWL Price Today: Werewolf Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Werewolf Therapeutics (HOWL) Stock Bid Wall (Smart Money Exits) 2026-04-20Stock Analysis Community - newser.com
HOWL Forecast, Price Target & Analyst Ratings | WEREWOLF THERAPEUTICS INC (NASDAQ:HOWL) - ChartMill
Geopolitics Watch: Does Werewolf Therapeutics Inc have consistent dividend growthExit Point & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Werewolf Therapeutics (NASDAQ:HOWL) Raised to “Hold” at Wall Street Zen - Defense World
HOWL Technical Analysis & Stock Price Forecast - Intellectia AI
HOWL Should I Buy - Intellectia AI
Investment Report: Is now the right time to enter Werewolf Therapeutics IncWeekly Trend Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Werewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid Price - TipRanks
HOWL PE Ratio & Valuation, Is HOWL Overvalued - Intellectia AI
Aug Action: Is now the right time to enter Werewolf Therapeutics Inc2026 Technical Patterns & Accurate Buy Signal Alerts - baoquankhu1.vn
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - bitget.com
Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c) - tipranks.com
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Earnings - AlphaStreet
Werewolf Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Werewolf Therapeutics Reports 2025 Financial Results and Advances Cancer Therapy Clinical Pipeline - geneonline.com
Werewolf Therapeutics (HOWL) faces going‑concern risk while IL‑2 and IL‑12 candidates show early responses - Stock Titan
Werewolf Therapeutics 10-K: Revenue $0M, Net Loss $(60.82)M - TradingView
Earnings Scheduled For March 27, 2026 - Benzinga
HOWL: Strategic review underway with improved financials and continued progress in oncology pipeline - tradingview.com
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Werewolf Therapeutics Inc Stock (HOWL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EVNIN LUKE | Director |
May 06 '26 |
Sale |
0.66 |
14,635 |
9,659 |
1,657,835 |
| EVNIN LUKE | Director |
May 05 '26 |
Sale |
0.69 |
6,860 |
4,733 |
1,672,470 |
| EVNIN LUKE | Director |
Apr 30 '26 |
Sale |
0.72 |
168,262 |
121,149 |
1,785,687 |
| EVNIN LUKE | Director |
May 01 '26 |
Sale |
0.73 |
58,394 |
42,628 |
1,727,293 |
| EVNIN LUKE | Director |
May 04 '26 |
Sale |
0.72 |
47,963 |
34,533 |
1,679,330 |
1.25%
3.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):